Tafamidis

ATTR Cardiomyopathy Drug Approved

This entry was posted in Cardiovascular Diseases and tagged hereditary transthyretin amyloid cardiomyopathy Tafamidis Treatment on by

The US FDA approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) for the treatment of wild-type or hereditary transthyretin amyloid (ATTR) cardiomyopathy based on a trial that showed a significant reduction in mortality, cardiovascular hospitalizations, and in decline in functional capacity and quality of life. The multicenter, international, double-blind, placebo-controlled, phase […]